(STE) STERIS - Ratings and Ratios
Sterilizers, Washers, Disinfectants, Surgical Tables, Sterility Assurance
STE EPS (Earnings per Share)
STE Revenue
Description: STE STERIS
STERIS plc (NYSE:STE) is a global provider of infection prevention products and services, operating through three main segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The company offers a diverse range of products and services, including cleaning chemistries, sterilization equipment, and testing services, catering to hospitals, healthcare providers, and pharmaceutical manufacturers.
STERIS Healthcare segment is a significant contributor, providing a broad portfolio of products and services for sterile processing departments, including automated endoscope reprocessing systems, sterilizers, and equipment management services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers, leveraging a network of contract sterilization and laboratory facilities. Meanwhile, the Life Sciences segment designs and manufactures consumable products, such as pharmaceutical detergents and sterilants, as well as equipment for research institutions and pharmaceutical manufacturers.
From a financial perspective, key performance indicators (KPIs) to monitor include revenue growth, gross margin expansion, and operating margin improvement. The companys return on equity (RoE) stands at 9.46%, indicating a moderate level of profitability. Additionally, the price-to-earnings (P/E) ratio of 37.44 and forward P/E of 22.99 suggest that the stock may be slightly overvalued, but with expected earnings growth, the forward multiple appears more reasonable. Other relevant KPIs include the companys debt-to-equity ratio, interest coverage, and cash conversion cycle, which can provide further insights into its financial health and operational efficiency.
In terms of growth prospects, STERIS is well-positioned to benefit from the increasing demand for infection prevention products and services, driven by the ongoing need for sterile processing and the growing pharmaceutical industry. The companys diversified product and service portfolio, combined with its global presence, provides a solid foundation for long-term growth. To further evaluate the companys potential, it is essential to analyze its research and development (R&D) investments, new product launches, and strategic acquisitions, which can drive future revenue and earnings growth.
STE Stock Overview
| Market Cap in USD | 24,611m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1992-06-01 |
STE Stock Ratings
| Growth Rating | 52.1% |
| Fundamental | 68.1% |
| Dividend Rating | 58.6% |
| Return 12m vs S&P 500 | -13.6% |
| Analyst Rating | 3.80 of 5 |
STE Dividends
| Dividend Yield 12m | 0.99% |
| Yield on Cost 5y | 1.47% |
| Annual Growth 5y | 7.20% |
| Payout Consistency | 100.0% |
| Payout Ratio | 24.5% |
STE Growth Ratios
| Growth Correlation 3m | 59.7% |
| Growth Correlation 12m | 54.7% |
| Growth Correlation 5y | 59.2% |
| CAGR 5y | 10.41% |
| CAGR/Max DD 3y | 0.52 |
| CAGR/Mean DD 3y | 1.53 |
| Sharpe Ratio 12m | -0.52 |
| Alpha | -17.08 |
| Beta | 0.988 |
| Volatility | 21.28% |
| Current Volume | 757.5k |
| Average Volume 20d | 489.6k |
| Stop Loss | 240.3 (-3%) |
| Signal | -0.77 |
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (646.6m TTM) > 0 and > 6% of Revenue (6% = 334.3m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 2.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 20.30% (prev 22.43%; Δ -2.12pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 1.26b > Net Income 646.6m (YES >=105%, WARN >=100%) |
| Net Debt (1.79b) to EBITDA (1.41b) ratio: 1.27 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (98.8m) change vs 12m ago -0.58% (target <= -2.0% for YES) |
| Gross Margin 44.13% (prev 43.13%; Δ 0.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.32% (prev 48.79%; Δ 5.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.88 (EBITDA TTM 1.41b / Interest Expense TTM 71.8m) >= 6 (WARN >= 3) |
Altman Z'' 4.26
| (A) 0.11 = (Total Current Assets 2.06b - Total Current Liabilities 926.6m) / Total Assets 10.40b |
| (B) 0.25 = Retained Earnings (Balance) 2.60b / Total Assets 10.40b |
| (C) 0.09 = EBIT TTM 924.6m / Avg Total Assets 10.26b |
| (D) 2.03 = Book Value of Equity 6.96b / Total Liabilities 3.44b |
| Total Rating: 4.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.08
| 1. Piotroski 9.0pt = 4.0 |
| 2. FCF Yield 3.46% = 1.73 |
| 3. FCF Margin 16.31% = 4.08 |
| 4. Debt/Equity 0.28 = 2.46 |
| 5. Debt/Ebitda 1.38 = 1.17 |
| 6. ROIC - WACC -0.86% = -1.08 |
| 7. RoE 9.73% = 0.81 |
| 8. Rev. Trend 59.53% = 2.98 |
| 9. Rev. CAGR 5.50% = 0.69 |
| 10. EPS Trend 49.65% = 1.24 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of STE shares?
Over the past week, the price has changed by -0.21%, over one month by +1.18%, over three months by +3.03% and over the past year by +2.71%.
Is STERIS a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of STE is around 236.59 USD . This means that STE is currently overvalued and has a potential downside of -4.53%.
Is STE a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the STE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 272.4 | 9.9% |
| Analysts Target Price | 272.4 | 9.9% |
| ValueRay Target Price | 265 | 6.9% |
Last update: 2025-09-16 04:41
STE Fundamental Data Overview
CCE Cash And Equivalents = 279.7m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 38.1834
P/E Forward = 24.6914
P/S = 4.4176
P/B = 3.5376
P/EG = 1.8975
Beta = 0.955
Revenue TTM = 5.57b USD
EBIT TTM = 924.6m USD
EBITDA TTM = 1.41b USD
Long Term Debt = 1.90b USD (from longTermDebt, last quarter)
Short Term Debt = 35.3m USD (from shortTermDebt, last quarter)
Debt = 1.94b USD (Calculated: Short Term 35.3m + Long Term 1.90b)
Net Debt = 1.79b USD (from netDebt column, last quarter)
Enterprise Value = 26.27b USD (24.61b + Debt 1.94b - CCE 279.7m)
Interest Coverage Ratio = 12.88 (Ebit TTM 924.6m / Interest Expense TTM 71.8m)
FCF Yield = 3.46% (FCF TTM 908.7m / Enterprise Value 26.27b)
FCF Margin = 16.31% (FCF TTM 908.7m / Revenue TTM 5.57b)
Net Margin = 11.61% (Net Income TTM 646.6m / Revenue TTM 5.57b)
Gross Margin = 44.13% ((Revenue TTM 5.57b - Cost of Revenue TTM 3.11b) / Revenue TTM)
Tobins Q-Ratio = 3.78 (Enterprise Value 26.27b / Book Value Of Equity 6.96b)
Interest Expense / Debt = 0.82% (Interest Expense 15.9m / Debt 1.94b)
Taxrate = 23.19% (184.7m / 796.2m)
NOPAT = 710.2m (EBIT 924.6m * (1 - 23.19%))
Current Ratio = 2.22 (Total Current Assets 2.06b / Total Current Liabilities 926.6m)
Debt / Equity = 0.28 (Debt 1.94b / last Quarter total Stockholder Equity 6.96b)
Debt / EBITDA = 1.38 (Net Debt 1.79b / EBITDA 1.41b)
Debt / FCF = 2.13 (Debt 1.94b / FCF TTM 908.7m)
Total Stockholder Equity = 6.64b (last 4 quarters mean)
RoA = 6.21% (Net Income 646.6m, Total Assets 10.40b )
RoE = 9.73% (Net Income TTM 646.6m / Total Stockholder Equity 6.64b)
RoCE = 10.82% (Ebit 924.6m / (Equity 6.64b + L.T.Debt 1.90b))
RoIC = 8.14% (NOPAT 710.2m / Invested Capital 8.73b)
WACC = 9.00% (E(24.61b)/V(26.55b) * Re(9.66%)) + (D(1.94b)/V(26.55b) * Rd(0.82%) * (1-Tc(0.23)))
Shares Correlation 3-Years: -72.73 | Cagr: -0.11%
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.37% ; FCFE base≈782.9m ; Y1≈965.8m ; Y5≈1.65b
Fair Price DCF = 213.7 (DCF Value 21.04b / Shares Outstanding 98.5m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 59.53 | Revenue CAGR: 5.50%
Rev Growth-of-Growth: 10.70
EPS Correlation: 49.65 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 16.52
Additional Sources for STE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle